Response to interferon-α treatment correlates with recovery of blood plasmacytoid dendritic cells in children with chronic hepatitis B

 Background/AimsTo investigate whether dendritic cell changes are associated with the efficacy of interferon-α treatment we longitudinally analyzed circulating dendritic cells in children chronically infected with hepatitis B virus (HBV) undergoing interferon-α treatment.MethodsThirty-one children with chronic hepatitis B (CHB) received interferon-α antiviral treatment for 52 weeks. Myeloid and plasmacytoid dendritic cell (pDCs) frequency and function were analyzed at weeks 0, 2, 12, 24, 36 and 52 in 22 CHB patients.ResultsAll patients exhibited an initially rapid decrease of circulating pDC numbers and CpG-induced endogenous interferon-α production within 2 weeks of interferon-α treatment. Subsequently, all responders displayed a continuous increase of both pDC numbers and function peaking around week 12. These responses were consequently accompanied by viral clearance, hepatitis B e antigen seroconversion, and the improvement of circulating myeloid dendritic cells and type 1 T helper cytokine levels. However, non-responders lacked these sequential responses compared with responders.ConclusionspDCs may actively correlate with interferon-α therapy-induced viral clearance in pediatric patients with CHB. The recovery of blood pDC number and function may represent a prognostic marker for favourable response to interferon-α treatment in chronic hepatitis B.